{"id":3326,"date":"2019-04-23T15:45:56","date_gmt":"2019-04-23T19:45:56","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2019\/"},"modified":"2026-09-24T00:09:41","modified_gmt":"2026-09-24T04:09:41","slug":"gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2019","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/23\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2019\/","title":{"rendered":"GenSight Biologics publie sa situation nette de tr\u00e9sorerie au 31 mars 2019"},"content":{"rendered":"\n<strong>Paris, France, le 23 avril 2019, 17h45 CEST <\/strong>\u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation nette de tr\u00e9sorerie au 31 mars 2019.\n\n&nbsp;\n\n<strong>Situation nette de tr\u00e9sorerie<\/strong>\n\nLa situation nette de tr\u00e9sorerie de GenSight Biologics s\u2019\u00e9tablissait \u00e0 24,0 millions d\u2019euros au 31 mars 2019, compar\u00e9e \u00e0 26,2 millions d\u2019euros au 31 d\u00e9cembre 2018.\n\nL\u2019acc\u00e9l\u00e9ration des d\u00e9penses \u00e0 partir du dernier trimestre 2018 refl\u00e8te essentiellement les derni\u00e8res \u00e9tapes du d\u00e9veloppement pharmaceutique de GS010, en pr\u00e9paration du d\u00e9p\u00f4t de demande d\u2019autorisation de mise sur le march\u00e9 en Europe. La Soci\u00e9t\u00e9 pr\u00e9voit d\u2019\u00eatre en mesure de d\u00e9poser le dossier fin 2019.\n\nLes d\u00e9penses op\u00e9rationnelles ont partiellement \u00e9t\u00e9 compens\u00e9es par le produit net de l\u2019augmentation de capital de 8 millions d\u2019euros souscrites par Sofinnova en f\u00e9vrier 2019.\n\n&nbsp;\n\n<strong>Nombre d\u2019actions composant le capital social<\/strong>\n\nAu 31 mars 2019, le nombre d\u2019actions composant le capital social de GenSight Biologics \u00e9tait de\n28 724 541 actions ordinaires.\n\nGenSight Biologics publiera sa position nette de tr\u00e9sorerie, et ses r\u00e9sultats financiers semestriels au 30 juin 2019, le 24 juillet 2019.\n\n&nbsp;\n<h3><strong>\u00c0 propos de GenSight\u00a0Biologics<\/strong><\/h3>\nGenSight Biologics S.A. (GenSight Biologics) est une soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central. Le portefeuille de recherche de GenSight Biologics s\u2019appuie sur deux plates-formes technologiques : le ciblage mitochondrial (<em>Mitochondrial Targeting Sequence<\/em>, ou MTS) et l\u2019optog\u00e9n\u00e9tique, visant \u00e0 pr\u00e9server ou restaurer la vision chez les patients atteints de maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine. Le candidat m\u00e9dicament le plus avanc\u00e9 de GenSight Biologics, GS010, est en Phase III pour le traitement de la neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL), une maladie mitochondriale rare qui conduit \u00e0 une perte irr\u00e9versible de la vue chez les adolescents et les jeunes adultes. En utilisant son approche de th\u00e9rapie g\u00e9nique, les candidats m\u00e9dicaments de GenSight Biologics sont destin\u00e9s \u00e0 offrir aux patients une r\u00e9cup\u00e9ration visuelle fonctionnelle durable apr\u00e8s une seule injection intra-vitr\u00e9enne dans chaque \u0153il.\n","protected":false},"excerpt":{"rendered":"<p>Paris, France, le 23 avril 2019, 17h45 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation nette de tr\u00e9sorerie au 31 [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[79],"news-type":[76,80],"post-year":[],"class_list":["post-3326","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-topic-company-and-personnel","news-type-corporate","news-type-finance"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics publie sa situation nette de tr\u00e9sorerie au 31 mars 2019 - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/23\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2019\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics publie sa situation nette de tr\u00e9sorerie au 31 mars 2019 - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le 23 avril 2019, 17h45 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation nette de tr\u00e9sorerie au 31 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/23\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2019\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2019-04-23T19:45:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:09:41+00:00\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2019\\\/04\\\/23\\\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2019\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2019\\\/04\\\/23\\\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2019\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"headline\":\"GenSight Biologics publie sa situation nette de tr\u00e9sorerie au 31 mars 2019\",\"datePublished\":\"2019-04-23T19:45:56+00:00\",\"dateModified\":\"2026-09-24T04:09:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2019\\\/04\\\/23\\\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2019\\\/\"},\"wordCount\":419,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2019\\\/04\\\/23\\\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2019\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2019\\\/04\\\/23\\\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2019\\\/\",\"name\":\"GenSight Biologics publie sa situation nette de tr\u00e9sorerie au 31 mars 2019 - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2019-04-23T19:45:56+00:00\",\"dateModified\":\"2026-09-24T04:09:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2019\\\/04\\\/23\\\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2019\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2019\\\/04\\\/23\\\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2019\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2019\\\/04\\\/23\\\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2019\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics publie sa situation nette de tr\u00e9sorerie au 31 mars 2019\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics publie sa situation nette de tr\u00e9sorerie au 31 mars 2019 - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/23\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2019\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics publie sa situation nette de tr\u00e9sorerie au 31 mars 2019 - GenSight Biologics","og_description":"Paris, France, le 23 avril 2019, 17h45 CEST \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation nette de tr\u00e9sorerie au 31 [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/23\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2019\/","og_site_name":"GenSight Biologics","article_published_time":"2019-04-23T19:45:56+00:00","article_modified_time":"2026-09-24T04:09:41+00:00","author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/23\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2019\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/23\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2019\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"headline":"GenSight Biologics publie sa situation nette de tr\u00e9sorerie au 31 mars 2019","datePublished":"2019-04-23T19:45:56+00:00","dateModified":"2026-09-24T04:09:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/23\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2019\/"},"wordCount":419,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/23\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2019\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/23\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2019\/","name":"GenSight Biologics publie sa situation nette de tr\u00e9sorerie au 31 mars 2019 - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2019-04-23T19:45:56+00:00","dateModified":"2026-09-24T04:09:41+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/23\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2019\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/23\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2019\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2019\/04\/23\/gensight-biologics-publie-sa-situation-nette-de-tresorerie-au-31-mars-2019\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics publie sa situation nette de tr\u00e9sorerie au 31 mars 2019"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3326","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3326"}],"version-history":[{"count":0,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3326\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3326"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3326"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3326"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3326"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3326"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3326"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3326"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}